TJPC(SH:600488)2024-03-28 16:00Financial Performance - In 2023, the company achieved operating revenue of CNY 3.78 billion, a 2.55% increase compared to CNY 3.69 billion in 2022[14]. - The net profit attributable to shareholders reached CNY 117.05 million, representing a significant increase of 230.60% from CNY 35.41 million in the previous year[14]. - The net cash flow from operating activities was CNY 783.01 million, up 19.81% from CNY 653.52 million in 2022[14]. - The weighted average return on net assets increased to 3.95%, up 2.76 percentage points from 1.19% in 2022[14]. - Basic and diluted earnings per share were both CNY 0.107, a remarkable increase of 234.38% compared to CNY 0.032 in 2022[14]. - The total assets decreased by 7.64% to CNY 6.14 billion from CNY 6.65 billion in 2022[14]. - The company reported a revenue of CNY 2.08 billion from steroid hormones and CNY 366 million from amino acids in its main business[22]. Dividend Distribution - The company plans to distribute a cash dividend of 0.87 RMB per 10 shares, totaling 95,172,143.16 RMB, resulting in a cash dividend payout ratio of 81.31%[4]. - The company reported a total distributable profit of 919,864,134.95 RMB as of December 31, 2023[4]. Product Development and Market Position - The company has accelerated product registration and increased sales regions and customer numbers, particularly focusing on the successful bids for six products in the national drug procurement[12]. - The company has developed a total of 17 dosage forms, including injections, ointments, and tablets, with a strong emphasis on quality management and compliance with GMP standards[8]. - The company has achieved domestic firsts in consistency evaluation for several products, enhancing its market competitiveness and brand recognition[12]. - The company operates two major industrial bases in Tianjin, focusing on the R&D, production, and sales of steroid hormones and amino acid raw materials[8]. Supply Chain and Relationships - The company has established stable and friendly relationships with qualified suppliers through years of supply chain management[10]. - The company has over 60% of its steroid hormone raw materials exported to more than 70 countries and regions across Asia, Europe, and America, with domestic sales covering nearly 100 cities[9]. Recognition and Management Practices - The company is recognized as a national high-tech enterprise and has received multiple honors, including being a leading technology enterprise in Tianjin[9]. - The company emphasizes lean management to reduce waste and improve production efficiency, ensuring better market responsiveness[12]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,376, a slight decrease from 43,611 in the previous month[18]. - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., held 50.69% of the shares, totaling 554,530,149 shares[18]. Export Performance - The company exported goods worth USD 13.24 million during the reporting period[22].